To determine the potential clinical relevance of the expression of PHD 2/3, HIF-α and VEGF-A proteins and their modulation by therapeutic doses of MSC, we have evaluated their incidence, intensity and cellular distribution in ccRCC (n = 88), head & neck (n = 210), and colorectal (n = 65) human primary cancer specimens. The gene discussed is VEGFA; the disease is cancer.